Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man
OBJECTIVE Brain natriuretic peptide (BNP) causes vasodilatation but the mechanisms by which this is accomplished are not fully known. The aim of the present study was to determine whether, besides KCa2+-channels, nitric oxide (NO) is involved in BNP-induced vasodilatation. METHODS We studied 10 heal...
Gespeichert in:
Veröffentlicht in: | Journal of hypertension 2002-03, Vol.20 (3), p.493-499 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 499 |
---|---|
container_issue | 3 |
container_start_page | 493 |
container_title | Journal of hypertension |
container_volume | 20 |
creator | van der Zander, Kim Houben, Alphons J. H. M Kroon, Abraham A De Mey, Jo G. R Smits, Paul A. B. M de Leeuw, Peter W |
description | OBJECTIVE Brain natriuretic peptide (BNP) causes vasodilatation but the mechanisms by which this is accomplished are not fully known. The aim of the present study was to determine whether, besides KCa2+-channels, nitric oxide (NO) is involved in BNP-induced vasodilatation.
METHODS We studied 10 healthy males twice, in random order, at an interval of 2 weeks. Experiments always started with infusion of BNP (8–16–32–64 pmol/dl per min) into the brachial artery. On the first day this infusion was followed by a second BNP infusion combined with the KCa2+-channel-blocker, tetraethylammonium (TEA, 0.1 mg/dl per min), and on the other day by BNP infusion combined with the NO-synthase inhibitor, l-N-monomethyl arginine (l-NMMA, 0.8 μmol/dl per min). The latter was then followed by a combined infusion of BNP, l-NMMA and TEA. All infusions were separated by a 1 h washout period. Forearm blood flow (FBF) was determined by venous occlusion plethysmography.
RESULTS Mean arterial pressure and heart rate did not change during any of the experiments. BNP alone induced a dose-dependent dilatation, which was similar on both days. TEA, l-NMMA, and their combination all reduced the BNP-induced dilatation (P < 0.05). The combined infusion had a significantly greater effect than TEA alone (P = 0.005). BNP infusions were associated with a significant increase in plasma cyclic guanosine monophosphate (cGMP) and C-type natriuretic peptide (CNP) (P < 0.05).
CONCLUSIONS BNP induces arterial vasodilatation not only by opening KCa2+-channels, but also via stimulation of NO production. In addition, BNP stimulates net CNP increase. |
doi_str_mv | 10.1097/00004872-200203000-00025 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71503875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71503875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4525-1a48ac40d8f09d82abed8d75851716ff93571ceac705c36e04e638fa0e793b303</originalsourceid><addsrcrecordid>eNp1kU-P1CAYh4nRuOPoVzC96K0KpRR6NBtXTTZ60TN5B95mcClUoLP67aXO6J4k4V_y_F7ggZCG0TeMjvItra1Xsms7SjvK666tvROPyI71krdCjOox2dFu4O3ARXdFnuX8vSJqlPwpuWJMScGZ3JG7z64kZ5r401lsINhmiQVyduvcmCOEgD43kLBx4RT9CW1dNIcEdQxQk2vCUuMLLmUr4IJdTYVOkKN1HgoUF8OWmSE8J08m8BlfXOY9-Xbz_uv1x_b2y4dP1-9uW9OLTrQMegWmp1ZNdLSqgwNaZaVQgkk2TNPIhWQGwUgqDB-Q9jhwNQFFOfIDp3xPXp_rLin-WDEXPbts0HsIGNesJROUbwL2RJ1Bk2LOCSe9JDdD-qUZ1Zto_Ve0_ida_xFdoy8vZ6yHGe1D8GK2Aq8uAGQDfkoQjMsPXH2EGPrtsv2Zu4--YMp3fr3HpI8Ivhz1_z6a_wYjypaA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71503875</pqid></control><display><type>article</type><title>Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>van der Zander, Kim ; Houben, Alphons J. H. M ; Kroon, Abraham A ; De Mey, Jo G. R ; Smits, Paul A. B. M ; de Leeuw, Peter W</creator><creatorcontrib>van der Zander, Kim ; Houben, Alphons J. H. M ; Kroon, Abraham A ; De Mey, Jo G. R ; Smits, Paul A. B. M ; de Leeuw, Peter W</creatorcontrib><description>OBJECTIVE Brain natriuretic peptide (BNP) causes vasodilatation but the mechanisms by which this is accomplished are not fully known. The aim of the present study was to determine whether, besides KCa2+-channels, nitric oxide (NO) is involved in BNP-induced vasodilatation.
METHODS We studied 10 healthy males twice, in random order, at an interval of 2 weeks. Experiments always started with infusion of BNP (8–16–32–64 pmol/dl per min) into the brachial artery. On the first day this infusion was followed by a second BNP infusion combined with the KCa2+-channel-blocker, tetraethylammonium (TEA, 0.1 mg/dl per min), and on the other day by BNP infusion combined with the NO-synthase inhibitor, l-N-monomethyl arginine (l-NMMA, 0.8 μmol/dl per min). The latter was then followed by a combined infusion of BNP, l-NMMA and TEA. All infusions were separated by a 1 h washout period. Forearm blood flow (FBF) was determined by venous occlusion plethysmography.
RESULTS Mean arterial pressure and heart rate did not change during any of the experiments. BNP alone induced a dose-dependent dilatation, which was similar on both days. TEA, l-NMMA, and their combination all reduced the BNP-induced dilatation (P < 0.05). The combined infusion had a significantly greater effect than TEA alone (P = 0.005). BNP infusions were associated with a significant increase in plasma cyclic guanosine monophosphate (cGMP) and C-type natriuretic peptide (CNP) (P < 0.05).
CONCLUSIONS BNP induces arterial vasodilatation not only by opening KCa2+-channels, but also via stimulation of NO production. In addition, BNP stimulates net CNP increase.</description><identifier>ISSN: 0263-6352</identifier><identifier>EISSN: 1473-5598</identifier><identifier>DOI: 10.1097/00004872-200203000-00025</identifier><identifier>PMID: 11875317</identifier><identifier>CODEN: JOHYD3</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject>Adult ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Clinical manifestations. Epidemiology. Investigative techniques. Etiology ; Cyclic GMP - blood ; Drug Combinations ; Enzyme Inhibitors - pharmacology ; Forearm - blood supply ; Humans ; Male ; Medical sciences ; Natriuretic Peptide, Brain - pharmacology ; Natriuretic Peptide, C-Type - blood ; Nitric Oxide - antagonists & inhibitors ; Nitric Oxide - physiology ; omega-N-Methylarginine - pharmacology ; Potassium Channel Blockers - pharmacology ; Potassium Channels - physiology ; Regional Blood Flow - drug effects ; Tetraethylammonium - pharmacology ; Vasodilation - drug effects ; Vasodilation - physiology ; Vasodilator Agents - pharmacology</subject><ispartof>Journal of hypertension, 2002-03, Vol.20 (3), p.493-499</ispartof><rights>2002 Lippincott Williams & Wilkins, Inc.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4525-1a48ac40d8f09d82abed8d75851716ff93571ceac705c36e04e638fa0e793b303</citedby><cites>FETCH-LOGICAL-c4525-1a48ac40d8f09d82abed8d75851716ff93571ceac705c36e04e638fa0e793b303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13575640$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11875317$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Zander, Kim</creatorcontrib><creatorcontrib>Houben, Alphons J. H. M</creatorcontrib><creatorcontrib>Kroon, Abraham A</creatorcontrib><creatorcontrib>De Mey, Jo G. R</creatorcontrib><creatorcontrib>Smits, Paul A. B. M</creatorcontrib><creatorcontrib>de Leeuw, Peter W</creatorcontrib><title>Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man</title><title>Journal of hypertension</title><addtitle>J Hypertens</addtitle><description>OBJECTIVE Brain natriuretic peptide (BNP) causes vasodilatation but the mechanisms by which this is accomplished are not fully known. The aim of the present study was to determine whether, besides KCa2+-channels, nitric oxide (NO) is involved in BNP-induced vasodilatation.
METHODS We studied 10 healthy males twice, in random order, at an interval of 2 weeks. Experiments always started with infusion of BNP (8–16–32–64 pmol/dl per min) into the brachial artery. On the first day this infusion was followed by a second BNP infusion combined with the KCa2+-channel-blocker, tetraethylammonium (TEA, 0.1 mg/dl per min), and on the other day by BNP infusion combined with the NO-synthase inhibitor, l-N-monomethyl arginine (l-NMMA, 0.8 μmol/dl per min). The latter was then followed by a combined infusion of BNP, l-NMMA and TEA. All infusions were separated by a 1 h washout period. Forearm blood flow (FBF) was determined by venous occlusion plethysmography.
RESULTS Mean arterial pressure and heart rate did not change during any of the experiments. BNP alone induced a dose-dependent dilatation, which was similar on both days. TEA, l-NMMA, and their combination all reduced the BNP-induced dilatation (P < 0.05). The combined infusion had a significantly greater effect than TEA alone (P = 0.005). BNP infusions were associated with a significant increase in plasma cyclic guanosine monophosphate (cGMP) and C-type natriuretic peptide (CNP) (P < 0.05).
CONCLUSIONS BNP induces arterial vasodilatation not only by opening KCa2+-channels, but also via stimulation of NO production. In addition, BNP stimulates net CNP increase.</description><subject>Adult</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Clinical manifestations. Epidemiology. Investigative techniques. Etiology</subject><subject>Cyclic GMP - blood</subject><subject>Drug Combinations</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Forearm - blood supply</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Natriuretic Peptide, Brain - pharmacology</subject><subject>Natriuretic Peptide, C-Type - blood</subject><subject>Nitric Oxide - antagonists & inhibitors</subject><subject>Nitric Oxide - physiology</subject><subject>omega-N-Methylarginine - pharmacology</subject><subject>Potassium Channel Blockers - pharmacology</subject><subject>Potassium Channels - physiology</subject><subject>Regional Blood Flow - drug effects</subject><subject>Tetraethylammonium - pharmacology</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilation - physiology</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0263-6352</issn><issn>1473-5598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU-P1CAYh4nRuOPoVzC96K0KpRR6NBtXTTZ60TN5B95mcClUoLP67aXO6J4k4V_y_F7ggZCG0TeMjvItra1Xsms7SjvK666tvROPyI71krdCjOox2dFu4O3ARXdFnuX8vSJqlPwpuWJMScGZ3JG7z64kZ5r401lsINhmiQVyduvcmCOEgD43kLBx4RT9CW1dNIcEdQxQk2vCUuMLLmUr4IJdTYVOkKN1HgoUF8OWmSE8J08m8BlfXOY9-Xbz_uv1x_b2y4dP1-9uW9OLTrQMegWmp1ZNdLSqgwNaZaVQgkk2TNPIhWQGwUgqDB-Q9jhwNQFFOfIDp3xPXp_rLin-WDEXPbts0HsIGNesJROUbwL2RJ1Bk2LOCSe9JDdD-qUZ1Zto_Ve0_ida_xFdoy8vZ6yHGe1D8GK2Aq8uAGQDfkoQjMsPXH2EGPrtsv2Zu4--YMp3fr3HpI8Ivhz1_z6a_wYjypaA</recordid><startdate>200203</startdate><enddate>200203</enddate><creator>van der Zander, Kim</creator><creator>Houben, Alphons J. H. M</creator><creator>Kroon, Abraham A</creator><creator>De Mey, Jo G. R</creator><creator>Smits, Paul A. B. M</creator><creator>de Leeuw, Peter W</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200203</creationdate><title>Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man</title><author>van der Zander, Kim ; Houben, Alphons J. H. M ; Kroon, Abraham A ; De Mey, Jo G. R ; Smits, Paul A. B. M ; de Leeuw, Peter W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4525-1a48ac40d8f09d82abed8d75851716ff93571ceac705c36e04e638fa0e793b303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Clinical manifestations. Epidemiology. Investigative techniques. Etiology</topic><topic>Cyclic GMP - blood</topic><topic>Drug Combinations</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Forearm - blood supply</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Natriuretic Peptide, Brain - pharmacology</topic><topic>Natriuretic Peptide, C-Type - blood</topic><topic>Nitric Oxide - antagonists & inhibitors</topic><topic>Nitric Oxide - physiology</topic><topic>omega-N-Methylarginine - pharmacology</topic><topic>Potassium Channel Blockers - pharmacology</topic><topic>Potassium Channels - physiology</topic><topic>Regional Blood Flow - drug effects</topic><topic>Tetraethylammonium - pharmacology</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilation - physiology</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Zander, Kim</creatorcontrib><creatorcontrib>Houben, Alphons J. H. M</creatorcontrib><creatorcontrib>Kroon, Abraham A</creatorcontrib><creatorcontrib>De Mey, Jo G. R</creatorcontrib><creatorcontrib>Smits, Paul A. B. M</creatorcontrib><creatorcontrib>de Leeuw, Peter W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Zander, Kim</au><au>Houben, Alphons J. H. M</au><au>Kroon, Abraham A</au><au>De Mey, Jo G. R</au><au>Smits, Paul A. B. M</au><au>de Leeuw, Peter W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man</atitle><jtitle>Journal of hypertension</jtitle><addtitle>J Hypertens</addtitle><date>2002-03</date><risdate>2002</risdate><volume>20</volume><issue>3</issue><spage>493</spage><epage>499</epage><pages>493-499</pages><issn>0263-6352</issn><eissn>1473-5598</eissn><coden>JOHYD3</coden><abstract>OBJECTIVE Brain natriuretic peptide (BNP) causes vasodilatation but the mechanisms by which this is accomplished are not fully known. The aim of the present study was to determine whether, besides KCa2+-channels, nitric oxide (NO) is involved in BNP-induced vasodilatation.
METHODS We studied 10 healthy males twice, in random order, at an interval of 2 weeks. Experiments always started with infusion of BNP (8–16–32–64 pmol/dl per min) into the brachial artery. On the first day this infusion was followed by a second BNP infusion combined with the KCa2+-channel-blocker, tetraethylammonium (TEA, 0.1 mg/dl per min), and on the other day by BNP infusion combined with the NO-synthase inhibitor, l-N-monomethyl arginine (l-NMMA, 0.8 μmol/dl per min). The latter was then followed by a combined infusion of BNP, l-NMMA and TEA. All infusions were separated by a 1 h washout period. Forearm blood flow (FBF) was determined by venous occlusion plethysmography.
RESULTS Mean arterial pressure and heart rate did not change during any of the experiments. BNP alone induced a dose-dependent dilatation, which was similar on both days. TEA, l-NMMA, and their combination all reduced the BNP-induced dilatation (P < 0.05). The combined infusion had a significantly greater effect than TEA alone (P = 0.005). BNP infusions were associated with a significant increase in plasma cyclic guanosine monophosphate (cGMP) and C-type natriuretic peptide (CNP) (P < 0.05).
CONCLUSIONS BNP induces arterial vasodilatation not only by opening KCa2+-channels, but also via stimulation of NO production. In addition, BNP stimulates net CNP increase.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>11875317</pmid><doi>10.1097/00004872-200203000-00025</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0263-6352 |
ispartof | Journal of hypertension, 2002-03, Vol.20 (3), p.493-499 |
issn | 0263-6352 1473-5598 |
language | eng |
recordid | cdi_proquest_miscellaneous_71503875 |
source | MEDLINE; Journals@Ovid Complete |
subjects | Adult Arterial hypertension. Arterial hypotension Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Clinical manifestations. Epidemiology. Investigative techniques. Etiology Cyclic GMP - blood Drug Combinations Enzyme Inhibitors - pharmacology Forearm - blood supply Humans Male Medical sciences Natriuretic Peptide, Brain - pharmacology Natriuretic Peptide, C-Type - blood Nitric Oxide - antagonists & inhibitors Nitric Oxide - physiology omega-N-Methylarginine - pharmacology Potassium Channel Blockers - pharmacology Potassium Channels - physiology Regional Blood Flow - drug effects Tetraethylammonium - pharmacology Vasodilation - drug effects Vasodilation - physiology Vasodilator Agents - pharmacology |
title | Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A25%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nitric%20oxide%20and%20potassium%20channels%20are%20involved%20in%20brain%20natriuretic%20peptide%20induced%20vasodilatation%20in%20man&rft.jtitle=Journal%20of%20hypertension&rft.au=van%20der%20Zander,%20Kim&rft.date=2002-03&rft.volume=20&rft.issue=3&rft.spage=493&rft.epage=499&rft.pages=493-499&rft.issn=0263-6352&rft.eissn=1473-5598&rft.coden=JOHYD3&rft_id=info:doi/10.1097/00004872-200203000-00025&rft_dat=%3Cproquest_cross%3E71503875%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71503875&rft_id=info:pmid/11875317&rfr_iscdi=true |